2-Hydroxy-11-(2-methylallyl)oxynoraporphine is a serotonin 5-HT2A and 5-HT2C receptor agonist of the noraporphine family. It is a synthetic compound and is an analogue of aporphine alkaloids like nuciferine, but shows agonism rather than antagonism of serotonin 5-HT2 receptors.
It is a potent full agonist or high-efficacy partial agonist of the serotonin 5-HT2A and 5-HT2C receptors. The drug's () values were 6.3 to 9.4nM (83–84%) at the serotonin 5-HT2A receptor and 8.0 to 9.8nM (95–103%) at the serotonin 5-HT2C receptor. It showed no agonistic activity at the serotonin 5-HT2B receptor at concentrations of up to 30,000nM. 2-Hydroxy-11-(2-methylallyl)oxynoraporphine was among the most potent serotonin 5-HT2A receptor agonists of a large series of assessed noraporphines.
The chemical synthesis of 2-hydroxy-11-(2-methylallyl)oxynoraporphine has been described. A variety of analogues of the drug with similar activity have also been described.
2-Hydroxy-11-(2-methylallyl)oxynoraporphine was first described in the scientific literature by Wangzhi Qin and colleagues in 2025. It had previously been patented in 2022.
See also List of miscellaneous serotonin 5-HT2A receptor agonists Aporphine alkaloids 11-Chloroasimilobine MQ02-439 (S)-Glaucine
References